Investment Banking Update



Stephens served as Co-Manager on the offering

Transaction Details

- On June 24, 2021, Alpha Teknova, Inc. ("Teknova") announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of \$16.00 per share
 - Teknova also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock
- Teknova's common stock is expected to begin trading on the Nasdaq Global Market on June 25, 2021, under the ticker symbol "TKNO"
- Teknova intends to use net proceeds from the offering to increase its manufacturing capacity and capabilities, improve operating efficiency, scale up its marketing, sales and R&D staff, to increase brand awareness, develop new products and services, attract new customers, pursue acquisition opportunities and for other general corporate purposes
- Following the IPO, entities affiliated with Telegraph Hill Partners will own approximately 65% of Teknova's outstanding common stock

According to the Company's Press Release

Teknova (Nasdaq: TKNO) provides custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.

Sources: Company filings and press release.

This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.

The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATIN: Equity Syndicate Desk, or from the Securities and Exchange Commission's website at www.sec.gov at the following link:

https://www.sec.gov/Archives/edgar/data/0001850902/000119312521194075/d83801ds1a.htm. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the notice of its acceptance given after the effective date.

"Stephens" is the brand name for a family of independent privately held financial services firms, including Stephens Europe Limited, which is authorized and regulated by the Financial Conduct Authority (Registered office 12 Arthur Street, London, EC4R 9AB, Registered number 8817024) and Stephens Inc. which is regulated by the United States Securities and Exchange Commission and the Financial Industry Regulatory Authority (Home Office: 111 Center Street, Little Rock, AR USA, 501-377-2000). Stephens Inc. is a member of NYSE and SIPC. For more information, visit www.stephens.com. © 2021 Stephens

